ArticleJournal of clinical pharmacology2020
Population Pharmacokinetics and Exposure-Response Analyses for the Most Frequent Adverse Events Following Treatment With Lemborexant, an Orexin Receptor Antagonist, in Subjects With Insomnia Disorder.
Article in Journal of clinical pharmacology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 22 citations in OpenAlex.
- Efficacy and safety of lemborexant in adults with insomnia: comparing Japanese and non-Japanese subgroups from the global, phase 3, randomized, double-blind, placebo-controlled SUNRISE 2 study.Journal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine · 2021Trial
- Canine Mdr1 Knockout MDCK Cells Reliably Estimate Human Small Intestinal Permeability (Molecular pharmaceutics · 2025Article
- Emerging and upcoming therapies in insomnia.Translational and clinical pharmacology · 2024Article
- Lemborexant levels in maternal serum, cord blood, and breast milk during pregnancy and lactation: A case report.PCN reports : psychiatry and clinical neurosciences · 2023Article
- Population pharmacokinetic modeling of daridorexant, a novel dual orexin receptor antagonist.CPT: pharmacometrics & systems pharmacology · 2023Article
- Targeting Orexin Receptors for the Treatment of Insomnia: From Physiological Mechanisms to Current Clinical Evidence and Recommendations.Nature and science of sleep · 2023Review
- Efficacy and safety of lemborexant over 12 months in Asian adults with insomnia disorder.Sleep medicine: X · 2022Article
- Evaluation of the CYP3A and CYP2B6 Drug-Drug Interaction Potential of Lemborexant.Clinical pharmacology in drug development · 2021Article
- Physiologically-based pharmacokinetic modeling to predict drug interactions of lemborexant with CYP3A inhibitors.CPT: pharmacometrics & systems pharmacology · 2021Article
- Effect of severe renal impairment on pharmacokinetics, safety, and tolerability of lemborexant.Pharmacology research & perspectives · 2021Article
- Population Pharmacokinetics and Exposure-Response Analyses for the Most Frequent Adverse Events Following Treatment With Lemborexant, an Orexin Receptor Antagonist, in Subjects With Insomnia Disorder.Journal of clinical pharmacology · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Lemborexant is a novel orexin receptor antagonist approved in the United States and Japan for the treatment of insomnia. This article describes the population pharmacokinetics (PK) of lemborexant and the relationship of its daily steady-state exposure (C
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.